Activity of TDT 067 (terbinafine in Transfersome) Against Agents of Onychomycosis, As Determined by Minimum Inhibitory and Fungicidal Concentrations

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2011 Mar 18

PMID 21411586

Citations 16

Authors

Mahmoud Ghannoum

Nancy Isham

Jacqueline Herbert

William Henry

Sam Yurdakul

Affiliations

Soon will be listed here.

Abstract

TDT 067 is a novel carrier-based dosage form (liquid spray) of 15 mg/ml of terbinafine in Transfersome that has been developed to deliver terbinafine to the nail bed to treat onychomycosis. In this study, we report the in vitro activities of TDT 067 against dermatophytes, compared with those of the Transfersome vehicle, naked terbinafine, and commercially available terbinafine (1%) spray. The MICs of TDT 067 and comparators against 25 clinical strains each of Trichophyton rubrum, T. mentagrophytes, and Epidermophyton floccosum were determined according to the CLSI M38-A2 susceptibility method (2008). Minimum fungicidal concentrations (MFCs) were determined by subculturing visibly clear wells from the MIC microtiter plates. TDT 067 demonstrated potent activity against the dermatophyte strains tested, with an MIC range of 0.00003 to 0.015 μg/ml. Overall, TDT 067 MIC(50) values (defined as the lowest concentrations to inhibit 50% of the strains tested) were 8-fold and 60-fold lower than those of naked terbinafine and terbinafine spray, respectively. The Transfersome vehicle showed minimal inhibitory activity. TDT 067 demonstrated lower MFC values for T. rubrum and E. floccosum than naked terbinafine and terbinafine spray. TDT 067 has more potent antifungal activity against dermatophytes that cause nail infection than conventional terbinafine preparations. The Transfersome vehicle appears to potentiate the antifungal activity of terbinafine. Clinical investigation of TDT 067 for the topical treatment of onychomycosis is warranted.

Citing Articles

3BS12-4 Extracellular Compounds as a Potential Biological Control Agent against .

Aphaiso P, Mahakhan P, Sawaengkaew J J Microbiol Biotechnol. 2024; 34(8):1671-1679.

PMID: 39081260 PMC: 11380522. DOI: 10.4014/jmb.2402.02053.

Newer Therapies in Dermatophytosis.

Poddar S, Das A, Hay R, Wollina U Indian J Dermatol. 2023; 68(5):515-519.

PMID: 38099134 PMC: 10718254. DOI: 10.4103/ijd.ijd_829_23.

Photodynamic Eradication of and .

Valkov A, Zinigrad M, Nisnevitch M Pathogens. 2021; 10(3).

PMID: 33668866 PMC: 7996248. DOI: 10.3390/pathogens10030263.

Keratin Biomembranes as a Model for Studying Onychomycosis.

Valkov A, Zinigrad M, Sobolev A, Nisnevitch M Int J Mol Sci. 2020; 21(10).

PMID: 32429167 PMC: 7278978. DOI: 10.3390/ijms21103512.

ONYCHOMYCOSIS: A Review of New and Emerging Topical and Device-based Treatments.

Kawa N, Lee K, Anderson R, Garibyan L J Clin Aesthet Dermatol. 2020; 12(10):29-34.

PMID: 32038746 PMC: 6937150.

References

Hanel H, Luc J, Vandermander J, Michel G . Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin. Skin Pharmacol. 1991; 4(2):89-94. DOI: 10.1159/000210929. View

Murdan S . Drug delivery to the nail following topical application. Int J Pharm. 2002; 236(1-2):1-26. DOI: 10.1016/s0378-5173(01)00989-9. View

Baran R, Sigurgeirsson B, de Berker D, Kaufmann R, Lecha M, Faergemann J . A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix.... Br J Dermatol. 2007; 157(1):149-57. DOI: 10.1111/j.1365-2133.2007.07974.x. View

Cevc G . Drug delivery across the skin. Expert Opin Investig Drugs. 2005; 6(12):1887-937. DOI: 10.1517/13543784.6.12.1887. View

Clayton Y . Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol. 1994; 130 Suppl 43:7-8. DOI: 10.1111/j.1365-2133.1994.tb06084.x. View

Tosti A, Hay R, Arenas-Guzman R . Patients at risk of onychomycosis--risk factor identification and active prevention. J Eur Acad Dermatol Venereol. 2005; 19 Suppl 1:13-6. DOI: 10.1111/j.1468-3083.2005.01282.x. View

Foster K, Ghannoum M, Elewski B . Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. 2004; 50(5):748-52. DOI: 10.1016/s0190-9622(03)02117-0. View

Canton E, Peman J, Viudes A, Quindos G, Gobernado M, Espinel-Ingroff A . Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis. 2003; 45(3):203-6. DOI: 10.1016/s0732-8893(02)00525-4. View

Welsh O, Welsh E, Ocampo-Candiani J, Gomez M, Vera-Cabrera L . Dermatophytoses in monterrey, méxico. Mycoses. 2006; 49(2):119-23. DOI: 10.1111/j.1439-0507.2006.01199.x. View

10.

Hay R . Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol. 1993; 29(1):S50-4. DOI: 10.1016/s0190-9622(08)81838-5. View

11.

Yenisehirli G, Bulut Y, Sezer E, Gunday E . Onychomycosis infections in the Middle Black Sea Region, Turkey. Int J Dermatol. 2009; 48(9):956-9. DOI: 10.1111/j.1365-4632.2009.04126.x. View

12.

Jaiswal A, Sharma R, Garg A . An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol. 2007; 73(6):393-6. DOI: 10.4103/0378-6323.37056. View

13.

Crawford F, Young P, Godfrey C, Bell-Syer S, Hart R, Brunt E . Oral treatments for toenail onychomycosis: a systematic review. Arch Dermatol. 2002; 138(6):811-6. DOI: 10.1001/archderm.138.6.811. View

14.

Ghannoum M, Chaturvedi V, Espinel-Ingroff A, Pfaller M, Rinaldi M, Lee-Yang W . Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes. J Clin Microbiol. 2004; 42(7):2977-9. PMC: 446243. DOI: 10.1128/JCM.42.7.2977-2979.2004. View

15.

Kokjohn K, Bradley M, Griffiths B, Ghannoum M . Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. Int J Dermatol. 2003; 42 Suppl 1:11-7. DOI: 10.1046/j.1365-4362.42.s1.4.x. View

16.

Havlickova B, Czaika V, Friedrich M . Epidemiological trends in skin mycoses worldwide. Mycoses. 2008; 51 Suppl 4:2-15. DOI: 10.1111/j.1439-0507.2008.01606.x. View

17.

Reinel D . Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. Dermatology. 1992; 184 Suppl 1:21-4. DOI: 10.1159/000247612. View

18.

Ghannoum M, Hajjeh R, Scher R, Konnikov N, Gupta A, Summerbell R . A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000; 43(4):641-8. DOI: 10.1067/mjd.2000.107754. View

19.

Tosti A, Piraccini B, Stinchi C, Colombo M . Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology. 1998; 197(2):162-6. DOI: 10.1159/000017990. View

20.

Roseeuw D . Achilles foot screening project: preliminary results of patients screened by dermatologists. J Eur Acad Dermatol Venereol. 1999; 12 Suppl 1:S6-9; discussion S17. View